Craft

Advanced
Chiasma

Chiasma

Revenue

$1.1 M

FY, 2020

Chiasma Summary

Company Summary

Overview
Chiasma is a biopharmaceutical company specializing in rare or chronic diseases. It develops and commercializes oral therapies, specifically Transient Permeability Enhancer (TPE) technology aimed at reducing the burden of chronic injections.
Type
Subsidiary
Status
Closed
Founded
2001
HQ
Needham, MA, US | view all locations
Website
https://chiasma.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Table of Contents

Key People

  • Raj Kannan

    Raj Kannan, Chief Executive Officer and President, Director

    • Anand Varadan

      Anand Varadan, Chief Commercial Officer

    • William Ludlam

      William Ludlam, Senior VP Clinical Development & Medical Affairs

      • John Doyle

        John Doyle, Chief Financial Officer

      LocationsView all

      2 locations detected

      • Needham, MA HQ

        United States

        140 Kendrick St Building C

      • Ness Ziona, Center District

        Israel

        5 Golda Me'ir St

      Chiasma Financials

      Summary Financials

      Revenue (Q1, 2021)
      $1.9M
      Gross profit (Q1, 2021)
      $1.9M
      Net income (Q1, 2021)
      ($30.5M)
      Cash (Q1, 2021)
      $24.6M
      EBIT (Q1, 2021)
      ($18.0M)

      Competitors and Similar Companies

      Compare competitors

      Footer menu

      Product

      Solutions

      Resources

      Company

      © Craft.co 2026
      Share price data provided by IEX